Tumor microenvironment

About

A tumor is a dysregulated, ever-evolving and growing ecosystem of cells. Although researchers have historically focused on its constituent cancer cells, it has become clear in recent years that most tumors also depend on a supporting cast of noncancerous cells for their nourishment, growth and survival. These include cells that help establish a blood supply and provide various forms of biochemical support as well as immune cells that suppress anti-tumor immune responses. Several Ludwig researchers are exploring how cells of the tumor microenvironment support malignant growth, with the aim of targeting such dependencies for cancer therapy. These efforts include Ludwig’s Tumor Atlas Project, a collaboration between five Ludwig-affiliated labs that’s using newly developed microscopy, genetic, and computational tools to “see” and determine precisely how tumor and immune cells interact in the tumor microenvironment, and how those interactions influence responsiveness to therapy.

Scientists

Webinars

Normalizing the tumor microenvironment to improve immunotherapy of cancer

Ludwig Harvard investigator Rakesh Jain discusses how the abnormal tumor vessels and matrix create a hostile microenvironment that fuels tumor progression and confers resistance to conventional and emerging cancer treatments.

You must enable Marketing cookies to watch this video.

Strategies to investigate and target the tumor microenvironment

Ludwig Lausanne’s Johanna Joyce introduces the general features of the tumor microenvironment; discusses critical functions of tumor-promoting myeloid cells in regulating cancer progression, metastasis and therapeutic resistance; and outlines current strategies for therapeutic targeting.

You must enable Marketing cookies to watch this video.

Convergence of the circadian clock and cancer

Ludwig Scientific Director Chi Van Dang has worked to unravel how the oncogene MYC links the aberrant metabolism of cancer cells to their unchecked proliferation.

You must enable Marketing cookies to watch this video.

Scale and complexity of hypoxia signaling pathways and their implications for cancer

Ludwig Oxford’s Peter Ratcliffe outlines the HIF hydroxylase pathway, discusses its evolution and considers its operation in health and disease.

You must enable Marketing cookies to watch this video.

Recent News

Notice
?

You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?

Continue
Cancel